Research
Hormonal
Higher starch intake is associated with lower levels of specific plasma proteins (adrenomedullin, IL1ra, FABP4, leptin, CCL20) that are themselves positively associated with increased CVD and mortality risk.
This finding suggests that moderate starch intake may help regulate inflammatory and adiposity-related proteins. However, since the association weakened after adjusting for BMI, maintaining a healthy weight is likely the primary driver of these benefits.
ModerateQualifiesMEDIUM confidence
concentrations of the following five among the 88 plasma proteins were found to be significantly and inversely associated with starch intake: adrenomedullin, interleukin-1 receptor antagonist protein (IL1ra), fatty acid-binding protein (FABP4), leptin, and C-C motif chemokine 20 (CCL20)
Why this rating
Observational association of proteins; causality is not established, and associations attenuated after BMI adjustment.
Source
Starch intake, amylase gene copy number variation, plasma proteins, and risk of cardiovascular disease and mortality
Huiping Li et al. · BMC Medicine · 2023
DOI 10.1186/s12916-022-02706-5
cohort · n=21268Cited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- High starch intake (top quartile, >28.8 E%) is associated with a significantly higher risk of cardiovascular disease and all-cause mortality compared to moderate intake (22.8-25.3 E%), creating a U-shaped risk curve.Good
- Higher AMY1 gene copy number does not significantly modify the risk of cardiovascular disease or mortality associated with starch intake.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →